You are here: Industry Insights > Oral Semaglutide

News List

Novo's Ozempic launch kicks into gear ahead of oral semaglutide FDA decision fiercepharma
August 11, 2019
Novo Nordisk has suffered some well-documented insulin woes, but now the company has not just two, but three GLP-1 drugs stepping up to drive growth. And if all goes well at the FDA, another big approval is on tap this year.
Novo Nordisk buys out Purdue pill plant to gear up for oral semaglutide fiercepharma
August 07, 2019
With its next-gen oral GLP-1 semaglutide up for an FDA approval, Novo Nordisk is hunting for opportunities to boost its supply chain. Now, with Purdue Pharma on the ropes, it has found one in North Carolina.
Diabetes coverage is improving, but could a shake-up be on the way with Novo’s oral semaglutide? fiercepharma
March 06, 2019
Payer pressure has been squeezing diabetes drugs, leading to some major sales difficulties and layoff rounds. As Bernstein analyst Wimal Kapadia observes, things are on the mend in terms of 2019 formulary coverage, but one drug could “disrupt them all.”
Novo data buttress its oral semaglutide case, this time in kidney-impaired patients fiercepharma
August 21, 2018
The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide fiercepharma
July 02, 2018
Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another.